Annual EBITDA
-$48.47 M
-$8.72 M-21.94%
December 31, 2023
Summary
- As of February 24, 2025, CMPX annual EBITDA is -$48.47 million, with the most recent change of -$8.72 million (-21.94%) on December 31, 2023.
- During the last 3 years, CMPX annual EBITDA has fallen by -$22.32 million (-85.32%).
- CMPX annual EBITDA is now -85.32% below its all-time high of -$26.16 million, reached on December 1, 2020.
Performance
CMPX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$11.77 M
+$2.81 M+19.24%
September 1, 2024
Summary
- As of February 24, 2025, CMPX quarterly EBITDA is -$11.77 million, with the most recent change of +$2.81 million (+19.24%) on September 1, 2024.
- Over the past year, CMPX quarterly EBITDA has increased by +$533.00 thousand (+4.33%).
- CMPX quarterly EBITDA is now -142.16% below its all-time high of -$4.86 million, reached on June 1, 2020.
Performance
CMPX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$53.59 M
-$314.00 K-0.59%
September 1, 2024
Summary
- As of February 24, 2025, CMPX TTM EBITDA is -$53.59 million, with the most recent change of -$314.00 thousand (-0.59%) on September 1, 2024.
- Over the past year, CMPX TTM EBITDA has dropped by -$2.03 million (-3.94%).
- CMPX TTM EBITDA is now -532.72% below its all-time high of -$8.47 million, reached on June 1, 2019.
Performance
CMPX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CMPX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.9% | +4.3% | -3.9% |
| 3 y3 years | -85.3% | +4.3% | -3.9% |
| 5 y5 years | -36.6% | +4.3% | -3.9% |
CMPX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.9% | +39.5% | -74.5% | +21.1% | -61.0% | +33.2% |
| 5 y | 5-year | -85.3% | +39.5% | -142.2% | +78.7% | -144.2% | +33.2% |
| alltime | all time | -85.3% | +39.5% | -142.2% | +78.7% | -532.7% | +33.2% |
Compass Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$11.77 M(-19.2%) | -$53.59 M(+0.6%) |
| Jun 2024 | - | -$14.58 M(+18.5%) | -$53.27 M(+3.3%) |
| Mar 2024 | - | -$12.31 M(-17.5%) | -$51.55 M(+6.3%) |
| Dec 2023 | -$48.47 M(+21.9%) | -$14.93 M(+30.2%) | -$48.48 M(+5.5%) |
| Sep 2023 | - | -$11.46 M(-10.9%) | -$45.96 M(-1.4%) |
| Jun 2023 | - | -$12.86 M(+39.3%) | -$46.61 M(+10.4%) |
| Mar 2023 | - | -$9.23 M(-25.6%) | -$42.23 M(+6.2%) |
| Dec 2022 | -$39.75 M(-50.4%) | -$12.40 M(+2.4%) | -$39.75 M(-0.4%) |
| Sep 2022 | - | -$12.11 M(+42.7%) | -$39.91 M(+19.9%) |
| Jun 2022 | - | -$8.49 M(+25.8%) | -$33.29 M(-58.4%) |
| Mar 2022 | - | -$6.75 M(-46.3%) | -$80.07 M(-0.1%) |
| Dec 2021 | -$80.19 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | -$12.56 M(+128.7%) | -$80.19 M(+7.2%) |
| Sep 2021 | - | -$5.49 M(-90.1%) | -$74.77 M(-3.9%) |
| Jun 2021 | - | -$55.27 M(+704.9%) | -$77.78 M(+184.1%) |
| Mar 2021 | - | -$6.87 M(-3.9%) | -$27.38 M(+4.7%) |
| Dec 2020 | -$26.16 M(-16.4%) | -$7.14 M(-16.0%) | -$26.16 M(+5.4%) |
| Sep 2020 | - | -$8.50 M(+74.9%) | -$24.81 M(+3.5%) |
| Jun 2020 | - | -$4.86 M(-13.9%) | -$23.98 M(-13.1%) |
| Mar 2020 | - | -$5.65 M(-2.6%) | -$27.59 M(+25.7%) |
| Dec 2019 | -$31.30 M(-11.8%) | -$5.80 M(-24.5%) | -$21.94 M(+35.9%) |
| Sep 2019 | - | -$7.67 M(-9.4%) | -$16.14 M(+90.6%) |
| Jun 2019 | - | -$8.47 M | -$8.47 M |
| Dec 2018 | -$35.49 M | - | - |
FAQ
- What is Compass Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Compass Therapeutics?
- What is Compass Therapeutics annual EBITDA year-on-year change?
- What is Compass Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Compass Therapeutics?
- What is Compass Therapeutics quarterly EBITDA year-on-year change?
- What is Compass Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Compass Therapeutics?
- What is Compass Therapeutics TTM EBITDA year-on-year change?
What is Compass Therapeutics annual EBITDA?
The current annual EBITDA of CMPX is -$48.47 M
What is the all time high annual EBITDA for Compass Therapeutics?
Compass Therapeutics all-time high annual EBITDA is -$26.16 M
What is Compass Therapeutics annual EBITDA year-on-year change?
Over the past year, CMPX annual EBITDA has changed by -$8.72 M (-21.94%)
What is Compass Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CMPX is -$11.77 M
What is the all time high quarterly EBITDA for Compass Therapeutics?
Compass Therapeutics all-time high quarterly EBITDA is -$4.86 M
What is Compass Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CMPX quarterly EBITDA has changed by +$533.00 K (+4.33%)
What is Compass Therapeutics TTM EBITDA?
The current TTM EBITDA of CMPX is -$53.59 M
What is the all time high TTM EBITDA for Compass Therapeutics?
Compass Therapeutics all-time high TTM EBITDA is -$8.47 M
What is Compass Therapeutics TTM EBITDA year-on-year change?
Over the past year, CMPX TTM EBITDA has changed by -$2.03 M (-3.94%)